Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (13)
Complete (1)

Showing 1-10 of 13

Sorted By:

A-Z
Z-A

Previous Next

(NSABP B-64) EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
participants planning to undergo chemo for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis
A092205_HNSCC: Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
PhIII Trial of Pembro vs Pembro/Cetux in Recurrent or Metastatic HN Squamous Cell Carcinoma with Platinum Refractory Disease
CAMBRIA-1: A Phase III Open-Label Randomised Study to Assess Efficacy & Safety of Extended Therapy with Camizestrant (AZD9833, Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in ER+/HER2- Early Breast Cancer & Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (enrollment paused 11-Apr-2025)
camizestrant vs ET in patients w/ ER+/HER2- early BC w/ risk for disease recurrence who completed treatment & adjuvant ET for 2-5 years. Duration of treatment is 60 months
GSK_219606 AZUR-2: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy vs Standard of Care in Pts With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
MK2870-032: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Study of sac-TMT for people with (TNBC) or (HR-low positive/HER2 negative) breast cancer who will have surgery to remove their breast cancer.
MK5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Ph 3 Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w/ mCRPC Prev. Treated w/ NHA) & Taxane-based Chemotherapy
MK5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (Enrollment paused 06Aug2025)
Ph 3 Study of MK-5684 vs Alt.Abiraterone Acetate or Enzalutamide in Pts w/ mCRPC) that Progressed On /After Prior Treatment With One Next-generation Hormonal Agent (NHA)
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemo to Ovarian Function Suppression + Endo Therapy in premenopausal pts w/pN0-1 ER-Positive/HER2-Negative
NRG-GY036: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
phase III trial compares olaparib for one year vs two years, with or without bevacizumab in BRCA 1/2 mutated or HRD+ stage III or IV ovarian cancer
NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial (Location: Yankton)
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage).

Previous Next